Ascidian Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Ascidian Therapeutics's estimated annual revenue is currently $8.1M per year.
- Ascidian Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Ascidian Therapeutics has 52 Employees.
- Ascidian Therapeutics grew their employee count by 4% last year.
Ascidian Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Executive Assistant to CEO | Reveal Email/Phone |
3 | Interim President & CEO | Reveal Email/Phone |
4 | Chief Technical Officer | Reveal Email/Phone |
5 | Chief Technology Officer | Reveal Email/Phone |
6 | Chief Financial & Business Officer | Reveal Email/Phone |
7 | SVP, Head Research | Reveal Email/Phone |
8 | VP, Intellectual Property Strategy | Reveal Email/Phone |
9 | VP, Clinical Development | Reveal Email/Phone |
10 | SVP, Head Operations | Reveal Email/Phone |
Ascidian Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Ascidian Therapeutics?
Gene therapy is entering a new era as the field moves forward. But current technologies cannot overcome the challenges of many diseases. Ascidian’s unique approach aims to unlock these doors and enable treatment for millions of patients worldwide.
keywords:N/AN/A
Total Funding
52
Number of Employees
$8.1M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6.8M | 52 | 24% | N/A |
#2 | $6.8M | 52 | N/A | N/A |
#3 | $15.1M | 52 | -4% | N/A |
#4 | $9.8M | 52 | 27% | N/A |
#5 | $10.3M | 52 | -9% | N/A |